Rationale

In 2016, Belgium launched the Next Generation Sequencing (NGS) Roadbook, consisting in 10 Actions, across the health care system, to facilitate the uptake of NGS in routine clinical practice. We compiled feedback on deployment of the NGS Roadbook from governmental stakeholders and beneficiaries: health policy makers, insurance providers, pathologists, geneticists, and oncologists.

Main findings

The Roadbook ensured the establishment of a Commission on Personalized Medicine and NGS testing guidelines. A national benchmarking trial ensued, and 10 networks of hospitals and laboratories adopted a reimbursement convention with the Belgian Health Insurance Agency. The Healthdata.be platform centralizes the collection of NGS metrics, and citizens were consulted on their views about NGS and genomics.

Conclusion

The Roadbook facilitated the implementation of NGS in routine (hemato-)oncology care in Belgium. Some challenges remain linked to data sharing and access by a wider range of stakeholders. Next steps include continuous monitoring of health outcomes and the budgetary impact.

中文翻译：

---

精准癌症医学：什么在比利时转化为临床应用？

基本原理

2016 年，比利时推出了下一代测序 (NGS) 路线手册，其中包括整个医疗保健系统的 10 项行动，以促进 NGS 在常规临床实践中的应用。我们收集了政府利益相关者和受益者对 NGS 路线手册部署的反馈意见：卫生政策制定者、保险提供者、病理学家、遗传学家和肿瘤学家。

主要发现

路线手册确保了个性化医疗委员会和 NGS 检测指南的建立。随后进行了国家基准试验，10 个医院和实验室网络通过了与比利时健康保险局的报销协议。Healthdata.be 平台集中收集 NGS 指标，并就他们对 NGS 和基因组学的看法咨询了公民。

结论

路线手册促进了 NGS 在比利时常规（血液）肿瘤治疗中的实施。一些挑战仍然与更广泛的利益相关者共享和访问数据有关。下一步包括持续监测健康结果和预算影响。